Xibrom (bromfenac ophthalmic solution)? 0.09%, the leading prescription topical ophthalmic NSAID in the United States, is the first twice-daily eye drop medication belonging to a group of medications called nonsteroidal anti-inflammatory drugs or NSAIDs. Xibrom is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract extraction.
Warnings, Precautions, Adverse Reactions
Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.
There is the potential for cross-sensitivity to acetylsalicylic acidphenylacetic acid derivatives, and other NSAIDs. Caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.
All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
The most commonly reported adverse experiences reported following use of Xibrom after cataract surgery include: abonormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and irritis. These events were reported in 2-7% of patients.
Dosage and Administration
One drop of XIBROM ophthalmic solution should be applied to the affected eye(s) two times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.
